Table 3. The expression of miR-21 and Bcl2 in Estrogen Receptor (ER), Progesterone Receptor (PR), and Human epidermal growth factor receptor 2 (HER2/neu) female patients in the different subtypes and clinical stages of breast cancer, pre- and post-chemotherapy (Mean ± SD). The numbers between brackets represent the number of patients.

	miR-21		Bcl2
	Pre	Post	Pre	Post
Estrogen Receptor (ER)
Positive (112)	17.33 ± 1.06	11.06 ± 1.34*	14.73 ± 0.88	5.96 ± 0.51*
Negative (67)	19.78 ± 2.23	16.63 ± 4.44	17.41 ± 2.30	11.87 ± 4.76*
Progesterone Receptor (PR)
Positive (106)	17.31 ± 1.06	11.06 ± 1.35*	14.73 ± 0.89	5.95 ± 0.51*
Negative (73)	19.61 ± 2.22	16.18 ± 4.53	17.18 ± 2.33	11.40 ± 4.84*
Human epidermal growth factor receptor 2 (HER2/neu)
Positive (63)	17.36 ± 1.11	11.11 ± 1.47*	14.84 ± 1.00	5.97 ± 0.58*
Negative (116)	18.73 ± 2.19	14.25 ± 4.44*	16.21 ± 2.28	9.37 ± 4.67*
Subtypes
Luminal A (66)	17.24 ± 1.00	11.03 ± 1.08*	14.60 ± 0.71	5.94 ± 0.40*
Luminal B (47)	17.43 ± 1.15	11.11 ± 1.63*	14.88 ± 1.06	5.97 ± 0.63*
HER2/neu (16)	17.17 ± 1.01	11.12 ± 0.86*	14.72 ± 0.81	5.98 ± 0.44*
Basal Like (50)	20.70 ± 1.72	18.49 ± 3.53	18.34 ± 1.84	13.88 ± 3.78*
Clinical Stage
I (12)	17.35 ± 0.92	10.86 ± 0.78*	14.80 ± 0.67	5.88 ± 0.33*
II (135)	17.78 ± 1.65	12.17 ± 3.16*	15.26 ± 1.71	7.10 ± 3.14*
III (32)	20.57 ± 1.94	18.13 ± 3.87	18.09 ± 1.97	13.56 ± 4.10*

Note: * Post-chemotherapy is significant as compared to pre-chemotherapy at the 0.05 level.